LLY’s orforglipron is an investigational, once-daily small-molecule oral GLP-1 receptor ... oral drug for obesity. The candidate also met the key secondary endpoint in the ACHIEVE-1 study ...

The pharma giant said its oral GLP-1 drug demonstrated significant efficacy results and a safety profile consistent with its ...

Shares of Eli Lilly LLY soared 14.3% on April 17 after data from a late-stage study showed that orforglipron achieved the ...

Image Source ... developing its oral obesity pill, amycretin, in a mid-stage study. Amycretin is a dual receptor agonist that targets two key gut hormones, GLP-1 and amylin.

LLY’s orforglipron is an investigational, once-daily small-molecule oral GLP-1 receptor agonist ... a version of this oral drug for obesity. The candidate also met the key secondary endpoint in the ...

It positions the pharma to dominate the oral GLP-1 market. The pill achieved 7.9% weight loss ... Valuation supports the potential for LLY stock to become the next stock to break through the ...

The results come just a few weeks after a once-weekly injectable GLP-1 drug CT-388 – also sourced ... announcement had a similar effect, with the stock up just over 5% at the time of writing.

The same news that helped Novo stock out yesterday ... submitted to the Food and Drug Administration an application to approve an oral form of its semaglutide GLP-1 weight loss drug.

The weight loss drug market could grow to $500 billion ... Investors are paying up to own the stock. The competitive landscape for GLP-1 agonist weight loss drugs has undergone a significant ...